fms related receptor tyrosine kinase 4
अंतिम अद्यतन 28 Jun 2022
मरीज की संपादकीय दिशानिर्देशों
- डाउनलोडडाउनलोड
- साझा करें
- Language
- चर्चा
- Ask Patient
- ऑडियो संस्करण
- Google पर पसंदीदा स्रोतों में जोड़ें
यह FLT4 gene provides instructions for making a protein called vascular endothelial growth factor receptor 3 (VEGFR-3), which regulates the development and maintenance of the lymphatic system. The lymphatic system produces and transports fluids and immune cells throughout the body. VEGFR-3 is turned on (activated) by two proteins called vascular endothelial growth factor C (VEGF-C) and vascular endothelial growth factor D (VEGF-D). When VEGF-C and VEGF-D attach (bind) to VEGFR-3, chemical signals are produced that regulate the growth, movement, and survival of lymphatic cells.
के लिए वीडियो चयन Genesवीडियो लाइब्रेरी
Normal function
यह FLT4 gene provides instructions for making a protein called vascular endothelial growth factor receptor 3 (VEGFR-3), which regulates the development and maintenance of the lymphatic system. The lymphatic system produces and transports fluids and immune cells throughout the body. VEGFR-3 is turned on (activated) by two proteins called vascular endothelial growth factor C (VEGF-C) and vascular endothelial growth factor D (VEGF-D). When VEGF-C and VEGF-D attach (bind) to VEGFR-3, chemical signals are produced that regulate the growth, movement, and survival of lymphatic cells.
Conditions referring to this gene or chromosome
Other names
FLT41
fms-related tyrosine kinase 4
vascular endothelial growth factor receptor 3
VEGFR3
VGFR3_HUMAN
Related patient information and medicines

Patient information leaflet
मुँह का कैंसर
Epidermal growth factor receptor monoclonal antibody (EGFR mAb) is one form of targeted therapy. Cetuximab is an EGFR mAb. Tyrosine kinase inhibitors (TKIs) are another. Immunotherapy is treatment that aims to boost the body's own immune system to destroy the cancer cells. It is also sometimes called biological therapy: Recombinant interleukin.

Patient information leaflet
क्रोनिक माइलॉयड ल्यूकेमिया
Treatment for the initial chronic phase The aim of treatment is to control the disease process, to ease any symptoms and to prevent (or delay) the progress... You may be advised to have one or more of the following treatments: Imatinib tablets. This medicine is known as a tyrosine kinase inhibitor. The chemical tyrosine kinase is made by the.

Patient information leaflet
मास्टोसाइटोसिस और मास्ट सेल विकार
If the condition is severe, surgery to remove the spleen (splenectomy), medicines that have an effect on ... Dr Sarah Jarvis , 28th September 2021 Midostaurin for treating advanced systemic mastocytosis The National Institute for Health and Care Excellence (NICE) has brought out new guidance on the use of midostaurin for people with mastocytosis..

Patient information leaflet
फाइब्रोमायल्जिया
फाइब्रोमायल्जिया है a condition which causes pain and tenderness in the muscles and soft tissues in different areas of the body, associated with unrefreshing sleep and physical tiredness. The word fibromyalgia means pain (-algia) coming from the muscles (my-) and fibrous tissues (fibro-) such as tendons and ligaments. Due to its wide range of.

Patient information leaflet
मैक्युलर डिजनरेशन
It is more common with increasing age. It is rare under the age of 60. It usually begins in one eye. About 5 in 100 people aged over 65 and about 12 in 100 people aged over 80 have AMD severe enough to cause serious visual impairment. Women are more likely than men to develop AMD. White people are more likely to develop AMD than those of African.

Patient information leaflet
यकृत कार्य परीक्षण
They include substances that are made in the liver or affected by the health of the liver cells, chemicals which are processed or excreted by the liver, and hormones that the liver makes. What are liver function tests used for. Liver function tests are aimed at giving a picture of the 'state' of your liver. They are a sensitive way of looking for.
अधिक पठन और संदर्भ
- fms related receptor tyrosine kinase 4; MedlinePlus, National Library of Medicine.
- Brice G, Child AH, Evans A, Bell R, Mansour S, Burnand K, Sarfarazi M, Jeffery S, Mortimer P. Milroy disease and the VEGFR-3 mutation phenotype. J Med Genet. 2005 Feb;42(2):98-102. doi: 10.1136/jmg.2004.024802.
- Butler MG, Dagenais SL, Rockson SG, Glover TW. A novel VEGFR3 mutation causes Milroy disease. Am J Med Genet A. 2007 Jun 1;143A(11):1212-7. doi: 10.1002/ajmg.a.31703.
- Evans AL, Bell R, Brice G, Comeglio P, Lipede C, Jeffery S, Mortimer P, Sarfarazi M, Child AH. Identification of eight novel VEGFR-3 mutations in families with primary congenital lymphoedema. J Med Genet. 2003 Sep;40(9):697-703. doi: 10.1136/jmg.40.9.697. No abstract available.
- Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet. 2000 Aug;67(2):295-301. doi: 10.1086/303019. Epub 2000 Jun 9.
- Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold DN. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet. 2000 Jun;25(2):153-9. doi: 10.1038/75997.
- Van Zanten M, Mansour S, Ostergaard P, Mortimer P, Gordon K. Milroy Disease. 2006 Apr 27 [updated 2021 Feb 18]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1239/
हमारे में दूसरों के साथ अपने विचार या अनुभव साझा करें रोगी समुदायों.
पेशेंट न्यूज़लेटर के लिए साइन अप करें
आपकी साप्ताहिक खुराक स्पष्ट, विश्वसनीय स्वास्थ्य सलाह की - जो आपको सूचित, आत्मविश्वासी और नियंत्रण में महसूस करने में मदद करने के लिए लिखी गई है।.
सदस्यता लेने पर आप हमारी स्वीकार करते हैं गोपनीयता नीति. आप किसी भी समय सदस्यता समाप्त कर सकते हैं। हम कभी भी आपका डेटा नहीं बेचते।.

